Advertisement


Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial

2023 ASCO Annual Meeting

Advertisement

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the chemotherapy-free patients treated with trastuzumab and pertuzumab, the 3-year invasive disease–free survival was 98.8%, with no distant metastases (Abstract LBA506).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Lisa A. Carey: Javier, it is such a pleasure to have the chance to talk with you about the PHERGain presentation here at ASCO 2023. You guys designed an incredibly ambitious trial a few years ago. You've published on the first primary endpoint with the pathologic complete response of a no-chemo component driven by knowledge of responsiveness identified as PET scan responders. And at ASCO 2023, we now have the key other secondary endpoint of invasive disease-free survival, does it work. So tell us a little bit about... If you would, frame the earlier publication of the PCR endpoint and the design of the trial and then catch us up on what's happening with outcomes. Javier Cortes: So thanks very much, Lisa. No. I think you're right. I think that when we have started to see that with anti-HER2 therapies without chemotherapy, we achieved impressive pathological and complete remissions, patients will start to [inaudible 00:01:15], "How can we move forward with a new strategy without the need of giving chemotherapy?" And that's why we decided the PHERGain that you said before. And the first primary endpoint observed that in patients who did start with trastuzumab and pertuzumab with no chemo and achieved a response by PET, we had about 38- Lisa A. Carey: And that was just after two cycles? Javier Cortes: After two cycles. Exactly. Exactly. So PET scan afterwards, response. And among those patients, almost 40%, 38, 37.9% of these patients had achieved pathological and complete remission. And these are the patients who continue with trastuzumab and pertuzumab with no chemotherapy. So chemotherapy was added or not depending on first PET response and second pathological, complete remission or not. Lisa A. Carey: Right. So in other words, there were really two opportunities to intervene if the patient looked like they might not be doing as well. Javier Cortes: Exactly. Lisa A. Carey: The first was non-response on PET. They went directly to traditional TCHP. Javier Cortes: Exactly. Lisa A. Carey: And then the second was if they had residual disease, they went to traditional TCHP. Javier Cortes: Exactly. Unfortunately, we did not include T-DM1 in this strategy because the KATHERINE results came later. So as you said, at ASCO 2023, we presented a second primary endpoint, which was invasive disease-free survival at three years. Let me tell you that we will continue with the follow-up to know the data at five and seven years. But the data were, in my opinion, very good. For the total number of patients, doesn't matter for the purpose of the endpoint if they received or not chemotherapy, for all patients, the invasive disease-free [inaudible 00:02:56] three years, was over 95%, 95.4%, which was very similar or even better to what we might expect with a classical chemo trastu-pertu from the very beginning. And it was amazing because in those patients who did never receive chemotherapy, and it was 30% of the total population, 30% is almost one third, these patients behaved greatly. So no metastasis at three years and the invasive disease-free survival was 98.8%, only one regional recurrence. Lisa A. Carey: And this is only trastuzumab, pertuzumab and if they were hormone receptor-positive endocrine therapy? Javier Cortes: That's correct. Lisa A. Carey: And they went through the whole thing. So it's a minority of them, but for those patients you have truly deescalated. I mean, we talk about deescalation in terms of getting rid of some of the chemotherapy, but in this case, for those 20% of patients, there is no chemo at all and the three year invasive disease-free survival was in excess of 98%. Javier Cortes: That's correct. Lisa A. Carey: Which is very wonderful. Javier Cortes: Of course we also showed the data in terms of toxicity and as expected, the treatment related adverse events, grade three, grade four, in these patients who never received chemotherapy, 1%. So just one patient having grade three neutropenia. So I think that also it increases the amazing quality of life for our patients. Lisa A. Carey: So Javier, put this in context of efforts to deescalate in the HER2 positive early breast cancer space. Your approach depends on PET scan availability, which is great but not always there. But there are a number of other... There are trials going on. There are biomarkers. Talk through where you think this is going. Javier Cortes: Well, that's an excellent comment. I think that we have to optimize not only the strategy of the treatment but also the strategy of the assessments and can we integrate different biomarker based platforms. For example, we are working on exploring HER2DX in this strategy, other biomarkers which are upcoming, and we are working with you also trying to optimize who are the patients who will benefit more or less, but also in terms of the different radiological techniques. We are analyzed the data of the PET scan and compare with the breast MRI. And that's something that we will present in further meetings. But I can tell you it is very, very similar. So maybe we can also deescalate the techniques to optimize for the community these type of strategies. Lisa A. Carey: Yeah. This is fabulous. And I have to say thank you. Thank you for designing a really innovative trial and one that was very courageous, eliminating chemotherapy is something we all want to do, but it's a scary thing to try, and being so successful at it, you and the PHERGain investigators and the patients participating. Javier Cortes: Thank you very, very much, Lisa.

Related Videos

Prostate Cancer

Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).

Colorectal Cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational status in patients with metastatic colorectal cancer and is efficacious in first-line treatment of FOLFIRI and cetuximab for patients with RAS wild-type disease (Abstract 3507).

Gynecologic Cancers

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Kathleen N. Moore, MD, of the Stephenson Oklahoma Cancer Center at the University of Oklahoma, discuss phase III results from the MIRASOL trial, which showed that mirvetuximab soravtansine-gynx prolonged overall survival vs investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer with high folate receptor-alpha expression. The findings suggest a new standard of care for this disease (Abstract LBA5507).

Lymphoma

Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).

Skin Cancer
Immunotherapy

Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab

Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).

Advertisement

Advertisement




Advertisement